plaquenil 200 mg film-coated tablet
sanofi-aventis philippines, inc.; distributor: sanofi-aventis philippines, inc. - hydroxychloroquine sulfate - film-coated tablet - 200 mg
plaquenil tablets film-coated
sanofi-synthelabo ltd. - hydroxychloroquine (hydroxychloroquine sulfate) - tablets film-coated - 200mg
plaquenil 200 mg film-coat. tabl.
sanofi belgium sa-nv - hydroxychloroquine sulfate 200 mg - eq. hydroxychloroquine 155 mg - film-coated tablet - 200 mg - hydroxychloroquine sulfate 200 mg - hydroxychloroquine
plaquenil 200mg tab film-coated tablet
sanofi-aventis ireland limited, ireland - hydroxychloroquine sulfate - film-coated tablet - 200 mg
plaquenil 200mg tab film-coated tablet
sanofi-synthlabo - hydroxychloroquine sulfate - film-coated tablet - 200 mg
plaquenil 200mg tab film-coated tablet
aventis pharma limited - hydroxychloroquine sulfate - film-coated tablet - 200 mg
plaquenil 200mg film-coated tablets
nm pharma limited 3/4, cantrija complex triq it-targa, il-maghtab naxxar nxr 6613 , malta - film-coated tablet - hydroxychloroquine sulfate 200 mg - antiprotozoals
hydroxychloroquine sulfate tablet
prasco laboratories - hydroxychloroquine sulfate (unii: 8q2869cnvh) (hydroxychloroquine - unii:4qwg6n8qkh) - hydroxychloroquine sulfate 200 mg - malaria hydroxychloroquine sulfate tablets are indicated for the treatment of uncomplicated malaria due to p. falciparum, p. malariae, p. ovale, and p. vivax . hydroxychloroquine sulfate tablets are indicated for the prophylaxis of malaria in geographic areas where chloroquine resistance is not reported. limitations of use in malaria - hydroxychloroquine sulfate tablets are not recommended for the treatment of complicated malaria. - hydroxychloroquine sulfate tablets are not effective against chloroquine or hydroxychloroquine-resistant strains of plasmodium species (see clinical pharmacology – microbiology ). hydroxychloroquine sulfate tablets are not recommended for the treatment of malaria acquired in geographic areas where chloroquine resistance occurs or when the plasmodium species has not been identified. - hydroxychloroquine sulfate tablets are not recommended for malaria prophylaxis in geographic areas where chloroquine resistance occurs. - hydroxychloroquine sulfate tablets do not prevent relapses
hydroxychloroquine sulfate tablet
aphena pharma solutions - tennessee, llc - hydroxychloroquine sulfate (unii: 8q2869cnvh) (hydroxychloroquine - unii:4qwg6n8qkh) - hydroxychloroquine sulfate 200 mg - malaria hydroxychloroquine sulfate tablets are indicated for the treatment of uncomplicated malaria due to p. falciparum, p. malariae, p. ovale, and p. vivax . hydroxychloroquine sulfate tablets are indicated for the prophylaxis of malaria in geographic areas where chloroquine resistance is not reported. limitations of use in malaria - hydroxychloroquine sulfate tablets are not recommended for the treatment of complicated malaria. - hydroxychloroquine sulfate tablets are not effective against chloroquine or hydroxychloroquine-resistant strains of plasmodium species (see clinical pharmacology – microbiology ). hydroxychloroquine sulfate tablets are not recommended for the treatment of malaria acquired in geographic areas where chloroquine resistance occurs or when the plasmodium species has not been identified. - hydroxychloroquine sulfate tablets are not recommended for malaria prophylaxis in geographic areas where chloroquine resistance occurs. - hydroxychloroquine sulfate tablets do not prevent relapses
hydroxychloroquine sulfate 200mg film-coated tablets
ipca produtos farmaceuticos unipessoal lda rua jose nogueira vaz no 8b 2625-099 povoa de santa iria , portugal - film-coated tablet - hydroxychloroquine sulfate 200 mg - antiprotozoals